313 related articles for article (PubMed ID: 25111236)
1. Liver involvement in early autosomal-dominant polycystic kidney disease.
Hogan MC; Abebe K; Torres VE; Chapman AB; Bae KT; Tao C; Sun H; Perrone RD; Steinman TI; Braun W; Winklhofer FT; Miskulin DC; Rahbari-Oskoui F; Brosnahan G; Masoumi A; Karpov IO; Spillane S; Flessner M; Moore CG; Schrier RW
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):155-64.e6. PubMed ID: 25111236
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease.
Takei R; Ubara Y; Hoshino J; Higa Y; Suwabe T; Sogawa Y; Nomura K; Nakanishi S; Sawa N; Katori H; Takemoto F; Hara S; Takaichi K
Am J Kidney Dis; 2007 Jun; 49(6):744-52. PubMed ID: 17533017
[TBL] [Abstract][Full Text] [Related]
3. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Brosnahan GM; Abebe KZ; Moore CG; Rahbari-Oskoui FF; Bae KT; Grantham JJ; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Miskulin DC; Steinman TI; Torres VE;
Am J Kidney Dis; 2018 May; 71(5):666-676. PubMed ID: 29306517
[TBL] [Abstract][Full Text] [Related]
5. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
van Aerts RMM; Kievit W; de Jong ME; Ahn C; Bañales JM; Reiterová J; Nevens F; Drenth JPH
Liver Int; 2019 Mar; 39(3):575-582. PubMed ID: 30225933
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated With the Development and Severity of Polycystic Liver in Patients With Autosomal Dominant Polycystic Kidney Disease.
Kim Y; Park HC; Ryu H; Kim YC; Ahn C; Lee KB; Kim YH; Han S; Bae EH; Jeong K; Choi J; Oh KH; Oh YK
J Korean Med Sci; 2023 Sep; 38(38):e296. PubMed ID: 37750370
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort.
Bae KT; Zhu F; Chapman AB; Torres VE; Grantham JJ; Guay-Woodford LM; Baumgarten DA; King BF; Wetzel LH; Kenney PJ; Brummer ME; Bennett WM; Klahr S; Meyers CM; Zhang X; Thompson PA; Miller JP;
Clin J Am Soc Nephrol; 2006 Jan; 1(1):64-9. PubMed ID: 17699192
[TBL] [Abstract][Full Text] [Related]
8. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
[TBL] [Abstract][Full Text] [Related]
9. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
Brosnahan GM; Abebe KZ; Rahbari-Oskoui FF; Patterson CG; Bae KT; Schrier RW; Braun WE; Chapman AB; Flessner MF; Harris PC; Perrone RD; Steinman TI; Torres VE;
Curr Hypertens Rev; 2017; 13(2):109-120. PubMed ID: 28460625
[TBL] [Abstract][Full Text] [Related]
10. Modelling polycystic liver disease progression using age-adjusted liver volumes and targeted mutational analysis.
Sierks D; Schönauer R; Friedrich A; Hantmann E; de Fallois J; Linder N; Fischer J; Herber A; Bergmann C; Berg T; Halbritter J
JHEP Rep; 2022 Nov; 4(11):100579. PubMed ID: 36246085
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
[TBL] [Abstract][Full Text] [Related]
12. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
Kim K; Trott JF; Gao G; Chapman A; Weiss RH
BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
[TBL] [Abstract][Full Text] [Related]
13. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP
Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274
[TBL] [Abstract][Full Text] [Related]
14. Analysis of baseline parameters in the HALT polycystic kidney disease trials.
Torres VE; Chapman AB; Perrone RD; Bae KT; Abebe KZ; Bost JE; Miskulin DC; Steinman TI; Braun WE; Winklhofer FT; Hogan MC; Oskoui FR; Kelleher C; Masoumi A; Glockner J; Halin NJ; Martin DR; Remer E; Patel N; Pedrosa I; Wetzel LH; Thompson PA; Miller JP; Meyers CM; Schrier RW;
Kidney Int; 2012 Mar; 81(6):577-85. PubMed ID: 22205355
[TBL] [Abstract][Full Text] [Related]
15. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
[TBL] [Abstract][Full Text] [Related]
16. Abdominal sonographic study of autosomal dominant polycystic kidney disease.
Nicolau C; Torra R; Bianchi L; Vilana R; Gilabert R; Darnell A; Brú C
J Clin Ultrasound; 2000; 28(6):277-82. PubMed ID: 10867665
[TBL] [Abstract][Full Text] [Related]
17. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR
J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
[TBL] [Abstract][Full Text] [Related]
18. Carbohydrate antigen 19-9 is significantly elevated in autosomal dominant polycystic kidney disease.
Fukasawa H; Kaneko M; Niwa H; Yasuda H; Kumagai H; Furuya R
Nephrology (Carlton); 2018 Mar; 23(3):210-216. PubMed ID: 28024168
[TBL] [Abstract][Full Text] [Related]
19. Blood pressure in early autosomal dominant polycystic kidney disease.
Schrier RW; Abebe KZ; Perrone RD; Torres VE; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Bae KT; Moore CG; Chapman AB;
N Engl J Med; 2014 Dec; 371(24):2255-66. PubMed ID: 25399733
[TBL] [Abstract][Full Text] [Related]
20. Kidney enlargement and multiple liver cyst formation implicate mutations in PKD1/2 in adult sporadic polycystic kidney disease.
Fujimaru T; Mori T; Sekine A; Mandai S; Chiga M; Kikuchi H; Ando F; Mori Y; Nomura N; Iimori S; Naito S; Okado T; Rai T; Hoshino J; Ubara Y; Uchida S; Sohara E
Clin Genet; 2018 Jul; 94(1):125-131. PubMed ID: 29520754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
